RX Review: Updates in Pediatric Food Allergy and Anaphylaxis for 2025 - Episode 1
RX Review: Advances in Pediatric Food Allergy and Anaphylaxis Management
Published on:
In this video, part 1 of a 5-part series, panelists discuss on recent advancements in pediatric food allergy and anaphylaxis management.
In this special report from HCPLive and Contemporary Pediatrics RX Review, Brian Schroer, MD, moderates a discussion with Colleen Kraft, MD, and Russell Traister, MD, on recent advancements in pediatric food allergy and anaphylaxis management.
Traister highlights omalizumab’s (Xolair) approval for food allergy, noting its potential for patients with multiple allergens. He also discusses the introduction of intranasal epinephrine, which offers an alternative to injectable auto-injectors. Recent data from the omalizumab trials suggest long-term tolerance benefits even after stopping treatment.
Kraft emphasizes the shift in primary care toward early introduction of allergenic foods at four to six months of age to prevent allergies. She also notes the growing role of oral immunotherapy (OIT) and non-injectable epinephrine in improving patient adherence.
Schroer underscores the movement toward personalized management, with allergists now assessing individual food tolerance thresholds. These innovations mark a shift from the traditional avoidance-only approach to a more tailored strategy that includes immune modulation and improved emergency treatment options.
Our Panelists:
Brian Schroer, MD, is an allergist immunologist at the Cleveland Clinic Children's Hospital. Board-certified in internal medicine, pediatrics, and allergy and immunology, Schroer serves as the moderator for this panel discussion.
Colleen Kraft, MD, is a clinical professor of Pediatrics at the Keck School of Medicine of USC and an attending physician at the Children’s Hospital Los Angeles. In addition to these roles, Kraft is also the former president of the American Academy of Pediatrics.
Russell Traister, MD, is a pediatric allergy and immunology specialist at Allegheny Health Network’s Pediatric Institute. Board-certified in allergy, immunology, and internal medicine, Traister serves as the third panelist for our discussion.
Relevant disclosures for Schroer include Genzyme, AstraZeneca, Amgen, GSK, and Sobi. Relevant disclosures for Kraft include Sanofi and Sobi. Relevant disclosures for Traister include Abbvie.
